Comparison of supraclavicular surgery plus radiotherapy versus radiotherapy alone in breast cancer patients with synchronous ipsilateral supraclavicular lymph node metastasis: a multicenter retrospective study.

[1]  Wen-Wen Zhang,et al.  Individualized Clinical Target Volume for Irradiation of the Supraclavicular Region in Breast Cancer Based on Mapping of the Involved Ipsilateral Supraclavicular Lymph Nodes. , 2022, International journal of radiation oncology, biology, physics.

[2]  W. Woodward,et al.  Contemporary Outcomes after Multimodality Therapy in Breast Cancer Patients Presenting with Ipsilateral Supraclavicular Node Involvement. , 2021, International journal of radiation oncology, biology, physics.

[3]  R. Gelber,et al.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. , 2021, The New England journal of medicine.

[4]  Min-hao Lv,et al.  Impact of Ipsilateral Supraclavicular Lymph Node Dissection (ISLND) for Breast Cancer Patients and a Nomogram for Predicting Ipsilateral Supraclavicular Pathological Complete Response (ispCR) , 2021, Annals of Surgical Oncology.

[5]  P. Austin,et al.  Missing Data in Clinical Research: A Tutorial on Multiple Imputation , 2020, The Canadian journal of cardiology.

[6]  Qiang Zhang,et al.  Comparison between surgery plus radiotherapy and radiotherapy alone in treating breast cancer patients with ipsilateral supraclavicular lymph node metastasis. , 2020, Gland surgery.

[7]  P. Neven,et al.  Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Armando Teixeira-Pinto,et al.  A practical guide to multiple imputation of missing data in nephrology. , 2020, Kidney international.

[9]  A. Taghian,et al.  Comparison of nodal target volumes definition in breast cancer radiotherapy according to RTOG versus ESTRO atlases. A practical review from the TransAtlantic Radiation Oncology Network (TRONE). , 2020, International journal of radiation oncology, biology, physics.

[10]  Lingmi Hou,et al.  Supraclavicular lymph node dissection with radiotherapy versus radiotherapy alone for operable breast cancer with synchronous ipsilateral supraclavicular lymph node metastases: a real-world cohort study. , 2020, Gland surgery.

[11]  S. Lee,et al.  Aggressive Surgical Excision of Supraclavicular Lymph Node Did Not Improve the Outcomes of Breast Cancer With Supraclavicular Lymph Node Involvement (KROG 16-14). , 2020, Clinical breast cancer.

[12]  J. Tisnado,et al.  A 3-Dimensional Mapping Analysis of Regional Nodal Recurrences in Breast Cancer. , 2019, International journal of radiation oncology, biology, physics.

[13]  Sung-Bae Kim,et al.  Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[14]  Sung-Bae Kim,et al.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.

[15]  Shulian Wang,et al.  Mapping Patterns of Ipsilateral Supraclavicular Nodal Metastases in Breast Cancer: Rethinking the Clinical Target Volume for High-risk Patients. , 2015, International journal of radiation oncology, biology, physics.

[16]  Sang‐wook Lee,et al.  Treatment Outcome of Breast Cancer with Pathologically Proven Synchronous Ipsilateral Supraclavicular Lymph Node Metastases , 2015, Journal of breast cancer.

[17]  Katherine J. Lee,et al.  The rise of multiple imputation: a review of the reporting and implementation of the method in medical research , 2015, BMC Medical Research Methodology.

[18]  Jian Yin,et al.  A retrospective study of different local treatments in breast cancer patients with synchronous ipsilateral supraclavicular lymph node metastasis. , 2013, Journal of cancer research and therapeutics.

[19]  C. Kerawala,et al.  Survey of UK practice for management of breast cancer metastases to the neck , 2012, Annals of the Royal College of Surgeons of England.

[20]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.

[21]  H. Kang,et al.  Outcomes of positron emission tomography-staged clinical N3 breast cancer treated with neoadjuvant chemotherapy, surgery, and radiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[22]  J. Werner,et al.  Postoperative morbidity after different types of selective neck dissection , 2010, The Laryngoscope.

[23]  M. Kenward,et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.

[24]  W. Woodward,et al.  Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. , 2007, International journal of radiation oncology, biology, physics.

[25]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[26]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Hortobagyi,et al.  Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Ik Jae Lee,et al.  Three-dimensional analysis of patterns of locoregional recurrence after treatment in breast cancer patients: Validation of the ESTRO consensus guideline on target volume. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  Mechthild Krause,et al.  ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.